AstraZeneca showcased positive early data on three experimental weight-loss drugs at ObesityWeek, highlighting its oral GLP-1 ...

Fasenra is the second biologic approved for the condition. The decision follows a positive opinion from the Committee for ...

AstraZeneca has added a late-stage rare disease ... Low calcium levels can also lead to symptoms like numbness, tingling, muscle twitching, spasms or cramps, abnormal heart rhythm, and seizures.

AstraZeneca is under scrutiny in China — as its top executive there and other personnel are being investigated by authorities ...

As AstraZeneca’s chronic obstructive pulmonary disease drug Breztri continues climbing toward blockbuster status, the Big Pharma is broadening its efforts to support people with COPD. | As AstraZeneca ...

AstraZeneca – which is a big player in oncology ... A big problem is that it is frequently diagnosed at a late stage, only after symptoms like cough, breathlessness, or chest/shoulder pain ...

"AstraZeneca’s Phase III trial of treatment for asthma meets its primary endpoint" was originally created and published by ...

Under the terms of the license agreement, Monopar will pay Alexion an upfront in the form of a cash payment and equity in Monopar. Future payments are based on tiered royalties on net sales and ...

AstraZeneca’s Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis ...

On Monday, AstraZeneca released topline data from BATURA Phase 3b trial of inhaled Airsupra (albuterol/budesonide) as an as-needed rescue medication in response to symptoms compared to as-needed ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Cambridge: AstraZeneca has announced that Fasenra (benralizumab) has been approved in the European Union (EU) as an add-on treatment for adult patients with relapsing or refractory ...